Health News Releases

  • Today September 21
August 29, 09:45
Sinovac Announces Change of Legal Representative of Sinovac Beijing
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that the Company’s subsidiary, Sinovac Biotech Co., Ltd. (“S
August 28, 13:45
SUSMED’s DTx Approved in Japan for the Treatment of Insomnia
SUSMED, Inc. (TOKYO:4263) announced that it obtained regulatory approval from the Ministry of Health, Labour and Welfare (the “MHLW”) of SUSMED Med CBT-i® App for Insomnia (the “product”). SUSMED is i
August 25, 14:40
Thermo Fisher Scientific Announces the Launch of the EXENT® Solution with IVDR Certification
Thermo Fisher Scientific, the world leader in serving science, today announced the commercial launch of the EXENT® Solution, after receiving IVDR certification[*]. The EXENT solution is a fully integr
August 24, 15:45
Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)
Royalty Pharma plc (Nasdaq: RPRX) and Ferring Pharmaceuticals today announced that Royalty Pharma has acquired a synthetic royalty on US net sales of Ferring’s Adstiladrin® (nadofaragene firadenovec-v
August 24, 09:15
Kenvue Becomes a Fully Independent Company Following Final Separation from Johnson & Johnson
Kenvue Inc. (NYSE: KVUE) (“Kenvue”) today announced its separation from Johnson & Johnson, marking its first day as a fully independent company. “This is a historic moment for Kenvue and with a sin
August 23, 13:15
Crown Bioscience Enables HanX Biopharmaceutical to Progress HX009 to Clinical Trials
Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, has announced that its collaborative work with HanX Biopharmaceutical Co., Ltd. (“HanX”), employing a uni
August 23, 10:30
BaroPace, Inc. Announced First Patient Enrolled in Non-Pharmacologic Hypertension and Heart Failure Treatment Trial
BaroPace Inc., a medical device company focused on the development of PressurePace™, a real-time physiologic control software and hardware to regulate cardiac pacemakers to treat resistant hypertensio
Masimo Root® with PVi® and SpHb® (Photo: Business Wire)
August 22, 14:10
New Study Evaluates the Use of Masimo PVi® As an Indicator of Fluid Responsiveness to Guide Goal-Directed Fluid Therapy in Elderly Patients Undergoing Gastrointestinal Surgery
Masimo (NASDAQ: MASI) today announced the findings of a prospective, randomized study published in Perioperative Medicine in which Dr. Yu Wang and colleagues at institutions in Shenzhen, Shaoguan, and
August 22, 09:00
Apollon Collaborates with Laser Biomedical Research Center of MIT to Develop Continuous Non-Invasive Glucose Monitoring Technology
Apollon Inc., a medtech startup based in Seoul, will collaborate with the Laser Biomedical Research Center (LBRC) at the Massachusetts Institute of Technology (MIT) with the aim of developing and cond
August 20, 09:45
Biocytogen’s Project Integrum Achieves Milestone Progress, Accelerating Antibody Business Growth
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced today that its Project Integrum has completed 2 core milestones, and its antibody business is now entering a new st
August 18, 11:30
RoslinCT Announces the Appointment of Dr. Derek Hei to its Scientific Advisory Board
RoslinCT, a leading contract development and manufacturing organization (CDMO) for Advanced Cell and Gene therapies, announced the appointment of Derek Hei, Ph.D., to its Scientific Advisory Board (SA
August 13, 10:35
CAS and Molecule.one Announce a Strategic Collaboration to Accelerate Drug Discovery
CAS, a division of the American Chemical Society specializing in scientific information solutions, and Molecule.one, a tech-bio leader in AI-based solutions for pharmaceutical chemistry, have establis
August 11, 10:35
KBI Biopharma, Inc. Continues to Strengthen Leadership and Expertise With Key Executive Appointments
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced four recent executive appointments to continue its momentum and vision of becoming a next-generation CDMO. Joining the company a
August 10, 11:10
Now Health International Celebrates Another Service Success
Award-winning International Private Medical Insurance (IPMI) provider Now Health International is celebrating its latest customer service success, having won another prestigious award, Customer Servic
August 09, 09:40
Graminex® Rye Pollen Achieves Novel Food Registration in China and Appoints Guangzhou Narnia Biotechnology as Their Authorized Distribution Partner
Graminex® announced today that it has achieved novel food registration in China for Rye Pollen and appointed Guangzhou Narnia Biotechnology as its distribution partner in China. Graminex®, based in
Duchenne Muscular Dystrophy (DMD); Progress of disease & gradual disability with aging, current ther
August 07, 13:55
Promising disease modifying approach to Duchenne muscular dystrophy with Neu-REFIX® Beta 1,3-1,6 glucan* from Japan; the first such clinical report
Duchenne Muscular Dystrophy (DMD) patients showed signs of disease progress slowing down, after oral consumption of Neu REFIX ß-glucan for 45 days along with routine medications. Clinical improvements
August 03, 16:15
The World Health Organization Includes the Cardiovascular Polypill Developed by the Spanish National Centre for Cardiovascular Research and Ferrer in its List of Essential Medicines
The cardiovascular polypill developed by the Spanish National Centre for Cardiovascular Research (CNIC) and Ferrer has been included by the World Health Organization (WHO) in its List of Essential Med
August 01, 16:24
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continues to advance its pipeline in both Human Pharma and Animal Health expanding across its key therapy areas. Currency-
Ferrer's 2022 Sustainability Report front page (Photo: Ferrer)
July 30, 14:30
Ferrer Allocates, on Average, More Than 40% of its Profits to Social and Environmental Projects for the Third Consecutive Year
The pharmaceutical company Ferrer, certified as a B Corp in 2022, has again shown that there is another way of doing business, with an ethical business approach that contributes to a better society. O
July 30, 13:45
Mouser Electronics Shares the Revolutionary Power of Digital Therapeutics in Latest Empowering Innovation Together Series
Mouser Electronics Inc., the industry's leading New Product Introduction (NPI) distributor with the widest selection of semiconductors and electronic components™, premieres its latest installment of t
July 30, 11:30
Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products
Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for the first quarter of fiscal year 2023 (period ended June 30, 2023). Takeda chief financial officer, Costa Saroukos, comment
July 28, 09:25
Medisca Expands Strategic Partnerships to Drive Patient Access to Critical Medications
Medisca has announced the expansion of a network of strategic partnerships aimed at securing and stabilizing worldwide access to high quality active pharmaceutical ingredients (APIs) for the preparati
July 27, 14:16
Galderma Achieves Record 2 B USD Net Sales for a Six-Month Period in H1 2023, as It Continues to Demonstrate Leading Execution and Innovation Capabilities in Dermatology
Galderma: · Galderma maintained strong momentum across all product categories reaching 2,003 M USD net sales in H1 2023, up 6.9% year-on-year on a constant currency basis · Growth primarily driven
July 27, 10:35
The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1
Takeda (TSE:4502/NYSE:TAK) today announced that data from the Phase 2 study of orexin receptor 2 (OX2R) agonist TAK-994 in patients with narcolepsy type 1 (NT1) was published in The New England Journa
July 27, 10:00
AmbioPharm, a Global Peptide CDMO
AmbioPharm, a worldwide leader in peptide API CDMO services, continues growth to meet capacity demands for late phase and commercial peptide production. A reliable peptide CDMO with manufacturing faci
25 per page50 per page75 per page100 per page